Ceramide induced mitophagy and tumor suppression  by Dany, Mohammed & Ogretmen, Besim
Biochimica et Biophysica Acta 1853 (2015) 2834–2845
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReviewCeramide induced mitophagy and tumor suppression☆Mohammed Dany, Besim Ogretmen ⁎
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA☆ This article is part of a Special Issue entitled: Mitopha
⁎ Corresponding author at: Department of Biochemistry
University of South Carolina, Jonathan Lucas Street, Roo
USA. Tel.: +1 843 792 0940; fax: +1 843 792 2556.
E-mail address: ogretmen@musc.edu (B. Ogretmen).
http://dx.doi.org/10.1016/j.bbamcr.2014.12.039
0167-4889/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 9 October 2014
Received in revised form 9 December 2014
Accepted 25 December 2014





Tumor suppressionSphingolipids are bioactive lipid effectors, which are involved in the regulation of various cellular signaling
pathways. Sphingolipids play essential roles in controlling cell inﬂammation, proliferation, death, migration,
senescence, metastasis and autophagy. Alterations in sphingolipid metabolism have been also implicated in
many human cancers. Macroautophagy (referred to here as autophagy) is a form of nonselective sequestering
of cytosolic materials by doublemembrane structures, autophagosomes, which can be either protective or lethal
for cells. Ceramide, a central molecule of sphingolipid metabolism is involved in the regulation of autophagy at
various levels, including the induction of lethalmitophagy, a selective autophagy process to target and eliminate
damagedmitochondria. In this review, we focused on recent studies with regard to the regulation of autophagy,
in particular lethal mitophagy, by ceramide, and aimed at providing discussion points for various context-
dependent roles and mechanisms of action of ceramide in controlling mitophagy. This article is part of a Special
Issue entitled: Mitophagy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Sphingolipids are membrane lipids with important functions in
regulating membrane ﬂuidity and subdomain structures. Advances in
sphingolipid research suggest that sphingolipids are highly bioactivemol-
ecules and have a great impact on cellular signaling and disease patho-
genesis [1]. Ceramide is one of the central molecules of sphingolipid
metabolism and plays a key role in the regulation of various cellular func-
tions, including cell proliferation, death, migration, and senescence [2].
Ceramide is intimately involved in cancer pathogenesis; alterations in
its metabolism are involved in controlling cancer initiation, progression,
and/or response of cancer cells to chemotherapeutic agents and radiation.
Endogenous levels of ceramide, especially C18-ceramide, are suppressed
inmany types of tumor tissues compared to non-cancerous counterparts.
Additionally, ceramide levels increase upon exposure of cancer cells to
stress-causing agents, such as cytokines, anticancer drugs, and radiation,
leading to cancer cell death and tumor suppression [2,3]. Ceramide-
mediated tumor suppression is regulated by various mechanisms such
as apoptosis, necroptosis, lethal autophagy, and mitophagy [4–8].
Mitophagy is a formof autophagy that results in selective degradation
of mitochondria through the autophagic machinery [9]. Ceramide plays a
key role in the regulation of general autophagy at many levels from initi-
ation to formation of autophagosomes [10]. Recently, we have begun togy.
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Several recent studies showed the ability of endogenous or exogenous
ceramides to cause cell death after accumulating in the mitochondria
[11–13]. Our recent study showed that mitochondrial ceramide acts as
a receptor for LC3-II [14]. Ceramide binding directly to LC3-II protein
leads to the recruitment of autophagosomes to damaged mitochondria,
resulting in lethal mitophagy [14]. This review will focus on the roles
and mechanism of action of ceramide in the regulation of mitophagy
and tumor suppression.2. Metabolism and biological roles of ceramide
2.1. Structure and metabolism of ceramide
Ceramide is a bioactive sphingolipid with a peculiar structure. It is
composed of a sphingosine backbone that is esteriﬁed to a fatty acyl
chain via an amide linkage at carbon 3 [1,2]. The variety in the length
of the fatty acyl chain generates many different ceramides, such as
C14- to C26-ceramides. A trans-double bond between carbons 4 and 5 in
the sphingosine backbone is required for its biological activity, as the
loss of the double bond generates dihydro-ceramide [1].
Ceramide lies at the center of sphingolipid metabolism: acting as a
substrate for the generation of more complex sphingolipids, or as a
product of the breakdown of complex sphingolipid molecules (Fig. 1).
As a substrate, ceramide is converted to sphingomyelin, ceramide-1-
phosphate, hexosylceramides, and other complex glycosphingolipids
and gangliosides [1]. As a product, ceramide can be generated by the
breakdown of these more complex sphingolipids by specialized enzymes
Fig. 1. Ceramide metabolic pathways. Ceramide lies at the center of sphingolipid metabolism. Ceramide de novo generation starts with a condensation reaction involving serine and
palmitoyl CoA by the enzyme serine palmitoyl CoA transferase (SPT), to generate 3-ketosphinganine, which is then converted to sphinganine or dihydrosphingosine. Then, ceramide
synthases (CerS1-6) transfer a fatty acyl CoA to the amino group yielding dihydroceramide which gets desaturated to ceramide by dihydro-ceramide desaturase enzyme (DES). Ceramide
can be generated back from sphingosine-1-phosphate with the help of S1P phosphatase (S1PP) and ceramide synthase (salvage pathway) or from sphingomyelin by sphingomyelinase
(SMase), fromglycosphingolipids, or fromceramide-1-phosphate by ceramide kinase (Cer-Kinase). As ametabolic outlet for ceramide, it is converted to sphingosine by the action of ceramidase.
Sphingosine kinases 1 and 2 (SK1/2) phosphorylate sphingosine to sphingosine-1-phosphate that can be further degraded by S1P lyase to hexadecanal and ethanolamine phosphate.
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(SM), and cerebrosidases which hydrolyze hexosylceramides [15].
De novo generation of ceramide begins with the condensation
of serine and palmitoyl CoA to form 3-ketosphinganine, and then
dihydrosphingosine (sphinganine) [16], involving multiple metabolic
enzymes. This is followed by the action of ceramide synthases 1–6
(CerS1–6) (also known as dihydro-ceramide synthases) that esterify
the dihydrosphingosine to generate dihydroceramide [17]. Ceramide
is then generated by the action of (dihydroceramide)-desaturase that
irreversibly inserts a double bond between carbons 4 and 5 [18].
Ceramide catabolism is regulated mainly by ceramidases, which
cleave ceramide to generate sphingosine. Sphingosine then gets phos-
phorylated by sphingosine kinases 1 or 2 (SphK1 or SphK2) to produce
sphingosine 1-phosphate (S1P). S1P can be lysed to hexadecanal and
ethanolaminephosphate by S1P lyase or dephosphorylated by S1P
phosphatases [19]. Hence, endogenous levels of ceramide increase
through de novo synthesis, activation of sphingomyelinases, or de-
creased clearance through the inhibition of glucosylceramide syn-
thase (GCS), sphingomyelin synthase (SMS), or ceramidase (CDase)
[20].
Sphingolipidmetabolism is highly compartmentalized in cells, as the
subcellular localization of different sphingolipid molecules and the
metabolic enzymes play key roles in this process [1]. For example,
CerS1–6 enzymes are localized in the endoplasmic reticulum (ER)
where de novo synthesis of ceramide occurs. For the synthesis of SM,
ceramide is transported from the ER to the Golgi apparatus by ceramide
transporter protein (CERT) in a non-vesicular fashion [21,22]. Similarly,
for the synthesis of glucosylceramide (GlcCer), ceramide is transported
to the Golgi by Fabb2 transporter [22]. Recently, a role for a lipid trans-
porter protein GLTPD1 for ceramide 1-phosphate, referred to as CPTP,
has been discovered, which plays a critical role in the regulation of in-
ﬂammation [23]. Ceramide is also found in the mitochondria where it
can be generated by neutral sphingomyelinase (N-SMase) in response
to increased reactive oxygen species (ROS) production [1]. Ceramide ac-
cumulation in the mitochondria can lead to ceramide stress-induced
mitochondrial fragmentation, and decrease in ATP production [14]. In
lysosomes, ceramide is mainly produced by acid sphingomyelinase
(A-SMase), and in the plasma membrane, ceramide is localized withinlipid rafts, which are specializedmembranemicrodomains that regulate
various signaling pathways [24].
2.2. Biological functions of ceramide synthases 1–6
Ceramide synthases 1–6 (CerS1–6) were ﬁrst identiﬁed in yeast as
longevity assurance gene 1 (LAG1). LAG1 regulates longevity in yeast in
a way that its deletion prolongs the replicative lifespan [17]. The mouse
homologue of LAG1 is LASS1, also known as the upstream of growth
and differentiation factor 1 (UOG1), which was discovered to speciﬁcally
regulate the synthesis of C18-ceramide [25,26]. There are at least six
mammalian LASS proteins that are currently known as CerS1–6 [17].
All of the CerS enzymes share a domain required for their enzymatic
activity to generate ceramide called TLC domain (TRAM, LAG1, and
CLN8 homology), which is made up of ﬁve predicted transmembrane
helices [27,28]. CerS2–6 also contain a HOX domain which CerS1 lacks
[29,30].
CerS1–6 exhibits some speciﬁcity for the generation of endogenous
ceramides with different fatty acid chain lengths [31,32]. For example,
CerS1 mainly generates ceramide with an 18-carbon containing fatty
acid chain (C18-ceramide), CerS4 generates both C18-ceramide and
C20-ceramide, and CerS5 and CerS6 generate mainly C16-ceramide, and
to a lesser extent, C12- and C14-ceramides. CerS2 and CerS3 are known
to generate very long chain C22–24- and C26-ceramides, respectively
[1–3,7,15,33].
Different species of ceramide with distinct fatty acyl chain lengths
have diverse biological functions (Table 1). For example, CerS1 and
CerS6, generating C18-ceramide and C16-ceramide respectively, have
opposing roles in cell death and proliferation in head and neck cancer
cells and tumors. CerS1/C18-ceramide axis leads to cancer cell death
and decreases head and neck tumor growth [34–36]. Increased levels
of serum C18-ceramide act as a potential biomarker to monitor patients'
response to chemotherapy [37]. On the other hand, C16-ceramide pro-
motes head and neck cancer cell proliferation and its increased serum
levels associate with a positive lymph node status in breast cancer
patients [38,39]. On the other hand, there are studies showing that
C16-ceramide is pro-apoptotic, whereas C24-ceramide protects from
cell death [40,41]. Thus, overall, distinct roles of ceramides appear to
Table 1
Diverse biological roles of ceramide synthases 1–6.
Ceramide synthase isoform Ceramide product Biological role
Ceramide synthase 1 C18-ceramide • Induces cancer cell death [34]
• Decreases tumor growth [35]
• CerS1 mutant mice have neurological disorders [42]
Ceramide synthase 2 C22–24-ceramide • C24-ceramide can protect from cell death [40,41]
• CerS2 knockout mice exhibit liver damage [44]
Ceramide Synthase 3 Ultra long chain ceramides N C26 • CerS3 knockout leads to trans-epidermal water loss leading to death after birth [203]
Ceramide synthase 4 C18- and C20-ceramide • CerS4 knockout mice exhibit severe alopecia with alterations in sebaceous glands and sebum contents [43]
Ceramide synthase 5 C12-, C14-, and C16-ceramide • Implicated in induction of autophagy mediated hypertrophy of cardiac myocytes [204]
Ceramide synthase 6 C12-, C14-, and C16-ceramide • Increases cancer cell proliferation [38]
• Increased expression associates with positive lymph node status [39]
• Induces chemotherapy mediated apoptosis [41]
• CerS6 knockout mice exhibit neurological/behavioral alterations [205]
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enzymes exhibit different phenotypes: mice that express a mutant
CerS1 (toppler mice) exhibit neurological disorders associated mainly
with alterations in Purkinjee cells; mice with genetic loss of CerS2
result in liver damage; mice with CerS6 knockout exhibit neurological/
behavioral alterations; and CerS4 knockout mice exhibit severe alopecia
with alterations in sebaceous glands and sebum contents [42,43]. The
demonstration of the distinct roles of CerS-generated ceramides in the
regulation of cell death is also consistentwith studies performed in Dro-
sophila and Caenorhabditis elegans that showed the distinct roles of
CerS-generated ceramides in these organisms [45–47]. Moreover, re-
cent evidence suggests that changes in the carbon length of the
sphingoid base of ceramides with 18 versus 16 carbons play roles in in-
ducing survival autophagy versus cell death in cardiomyocytes [48].
2.3. Cancer suppressing role of ceramide
Ceramide induces a variety of anti-proliferative responses such as
programmed cell death, cell cycle arrest, senescence, and differentiation.
Indeed, studies show that ceramide is involved in apoptosis, necroptosis,
lethal autophagy, and mitophagy, all of which decrease cancer cell via-
bility [14,49–51]. Exogenously supplied ceramides (C2–C18-ceramides),
also have anti-proliferative activities when added to cells in culture [11,
12,52]. Thus, ceramide metabolism has a signiﬁcant role in suppressing
cancer progression, and ceramide is emerging as a tumor suppressor
lipid.
Ceramide is generated during stress conditions such as hypoxia,
growth factor withdrawal, hyperthermia, and DNA damage which then
mediates cell death [53]. In addition, there is an increase in ceramide
levels during the activation of extrinsic apoptosis via FAS/FAS ligand path-
way or tumor necrosis factor (TNF)-alpha pathway [54]. Ionizing radia-
tion causes ceramide formation by activating A-SMase while androgen
ablation in prostate cancer cells induces de novo generation of ceramide,
leading to cell death [55–57].
Onemechanismbywhich ceramide leads to cell death is by activating
protein phosphatases PP1 and PP2A [58]. PP2A is a tumor suppressor
protein that acts as a phosphatase to regulate signaling of many targets
including Akt, c-Myc, and Bcr-Abl [59,60]. Ceramide binds to the biologi-
cal inhibitor of PP2A, I2PP2A or SET oncoprotein, leading to PP2A reacti-
vation. PP2A can then dephosphorylate and inactivate several anti-
apoptotic proteins such as Bcl-2 and AKT, or c-Myc [50,61]. Interestingly,
SET/I2PP2A oncoprotein preferentially associates with endogenous
C18-ceramide compared with other ceramide species [62]. This speciﬁc-
ity for binding to a speciﬁc species of ceramide is also evident in CERT
binding preferentially to C16- and C18-ceramides but not very long
chain ceramides [63]. Ceramide interacts with another phosphatase,
PP1, which inactivates the pro-apoptotic protein Bid [54]. Moreover,
ceramide-PP1 is involved in the regulation of retinoblastoma protein
(RB), a tumor suppressor protein that plays an important role in cell
cycle regulation. Ceramide treatment can dephosphorylate and activate
RB leading to cell cycle arrest in cancer cells [64]. In addition, ceramidegenerated in lysosomes by A-SMase activates cathepsin D by inducing
autocatalytic proteolysis, resulting in Bid cleavage and caspase activa-
tion [65,66].
Anothermechanism that associates with the tumor suppressor roles
of ceramide is its regulation of telomere length by acting as an upstream
regulator of telomerase. Studies showed that ceramide accumulation in
lung cancer cells inhibits telomerase expression by inactivating c-Myc
transcription factor, which is an activator of the human telomerase
reverse transcriptase (hTERT) promoter, via increased ubiquitination
and proteasome mediated degradation. The inactivation of telomerase
prevents the cancer cell from elongating the telomeric ends of the chro-
mosomes after each replication cycle, leading eventually to cell death
[67,68].
Ceramide is also involved in pathways that lead to quiescence and
senescence in cancer cells. For example, ceramide inactivates cyclin
dependent kinase 2 (CDK2), and upregulates the expression of CDK
inhibitors p21 and p27 inWi-38 ﬁbroblasts and nasopharyngeal carcino-
ma cells, respectively [69–71]. In addition, exogenous supply of ceramide
to ﬁbroblasts cultured at low passage induces the biochemical and mor-
phological features of senescence [1,72]. By inducing senescence, cer-
amide helps in the suppression of key mitogenic pathways, leading to
tumor suppression [73].
Because of these pro-death characteristics, ceramide analogues or
mimetics have the potential to act as anti-cancer agents. Endogenous
accumulation of ceramide might also be beneﬁcial to suppress tumor
growth. One example is the group of ceramide analogues, ceramidoids
or pyridinium ceramides, which preferentially accumulate in the
mitochondria/nuclei, and suppress the tumor growth of lung, breast,
and head and neck squamous cell carcinomas [52,74]. Themitochondrial
accumulation of pyridinium ceramides results in mitochondrial perme-
ability transition and either caspase-dependent apoptosis or mitophagy
[14,74]. Another example is the group of glucosylceramide synthase
inhibitors (PPMP and PPPP) that lead to the accumulation of ceramide,
which decrease glucosylceramide generation, and suppress solid tumor
growth [75,76]. Ceramide can also be delivered exogenously in PEGylated
nanoliposomes. Studies using these liposomes show that this delivery
method of ceramide decreases phosphorylation of AKT, stimulates the
activity of caspase 3/7, and prevents the growth of breast cancer cells
in vitro and in vivo [77,78].
3. General autophagy and its regulation by ceramide
3.1. Progression of autophagy
Autophagy, or self-eating in Greek, describes themechanismutilized
by the cell to self-digest internal organelles and misfolded proteins
using lysosomal hydrolytic enzymes [79]. Autophagy starts with the
formation of cup shaped structures called phagophores, also known as
isolation membranes, which will elongate to engulf organelles and
other cytoplasmic components. The maturation of the phagophores
leads to the formation of an autophagosome that fuses with lysosomes
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sosomal enzymes start the digestion process and the rate of breakdown
of the cellular components is referred to as lysosomal ﬂux. Autophagy
plays a critical role in physiology and cellular homeostasis, allowing
the cells to recycle nutrients fromdigested organelles at times of starva-
tion and remove aberrantly folded proteins [81–84]. Dysregulation in
autophagy has been implicated in various human diseases such as neu-
rodegenerative disorders, cardiovascular diseases, and cancer [84–89].
The discovery of autophagy genes (Atg) in yeast had a great impact
on our understanding of themechanisms of autophagy process. Most of
the Atg genes are conserved in humans and play various roles including
autophagy initiation, autophagosome formation and maturation
[90–92]. During initiation, Atg1 forms a complex with ULK (Unc-51
like kinase) that integrates inputs from mTOR signaling [87,93–95].
During autophagosome formation, Atg9 allows for membrane addition
and retrieval to and from sites of autophagosome biogenesis [83,96],
while Atg6 (or Beclin 1 in mammals) forms a multimeric complex
with Atg14, Vps34/PI3kinase, and Vps15 [94,96–98]. In addition, during
autophagosome formation, Atg12 is activated by the enzyme Atg7 (E1-
like ubiquitin ligase) and then transferred to Atg10 (E2-like ubiquitin li-
gase) to be conjugated to Atg5 (E3-like ubiquitin ligase), forming an
autophagosomal precursor. Finally, Atg8 is required during the matura-
tion phase [93,95,97,100,101].
LC3, mammalian homologue of Atg8, which plays important roles
for the maturation of autophagosomes, has three isoforms: LC3A, LC3B
and LC3C. GABARAP and GATE16 are also mammalian homologues of
Atg8 [102]. LC3 is synthesized in the cell in its cytosolic form, LC3-I,
with a carboxy terminal glycine (Gly120) [102]. During autophagy, LC3
is cleaved by Atg4 protease and then activated by Atg7 to be trans-
ferred to Atg3 (E2-like ubiquitin ligase) [80,103]. This allows the
Gly120 residue on the carboxyl terminal to be conjugated to phosphati-
dylethanolamine (PE) to form LC3-II. This allows its docking to the
membranes, leading to membrane closure and formation of a mature
autophagosome [104]. This sets LC3-II as a well-established marker of
autophagosomes.
3.2. Autophagy paradox: cell survival or death regulation
Autophagy was initially discovered as a mechanism occurring at a
low rate to remove protein aggregates and damaged organelles that
are otherwise toxic for the cell [81]. In addition, autophagy is considered
as a vital process during metabolic stress or nutrient deprivation, in
which the degradation of organelles provides macromolecules and
nutrients that maintain energy production and the basic cellular func-
tions [79,82,99]. Mechanistically, several reports show that upon cell
starvation, LC3-I is modiﬁed to LC3-II to promote autophagy [80]. In
vivo, GFP-LC3 localizes in punctate structures in heart and skeletal
muscle tissues in transgenic mice when the animals were under fasting
conditions [102,105]. These functions of autophagy provide pro-survival
and cyto-protective mechanisms.
Recently, autophagy was found to be a pro-death mechanism espe-
cially if it occurs for a sustained period of time with a high intensity.
Cells with sustained upregulation of autophagic activity became
atrophic with loss of vital organelles and cellular functions [106]. This
suggests that over-activated autophagy can lead to cell death when
associated with major elimination of essential organelles. Moreover,
studies indicate that autophagy can lead to cell death via its ability to de-
grade cyto-protective proteins such as catalase, an anti-oxidant enzyme
[107]. Autophagy can also result in cell death by upregulating apoptosis
or necroptosis [108–110]. One particular example is the case of Atg5,
which during autophagy can translocate to the mitochondria to induce
mitochondrial membrane depolarization and caspase dependent cell
death [111]. However, autophagic cell death, also known as lethal
autophagy, or autosis, can be achieved independent of apoptosis or
necroptosis. This type of cell death is rescued by suppression of autoph-
agy by pharmacological or genetic approaches, and involves the actionof autophagy genes and lysosomal ﬂux during the death process [106,
108,112–114].
3.3. Autophagy in cancer
There are several lines of evidence supporting that autophagy is a
tumor-suppressor mechanism: Cancer cells have increased oxidative
and metabolic stress that cause chromosomal abnormalities, DNA strand
breaks, and gene mutations. Autophagy helps in scavenging reactive ox-
ygen species by removing the damaged organelles, thus preventing the
genetic abnormalities that might otherwise lead to oncogene activation
or tumor suppressor gene inactivation [115–118]. Some cancer cells
suppress autophagy as a mechanism to avoid the quality control during
oxidative stress, DNA damage, and genetic instability [119]. One example
to illustrate this is the role of autophagy in the turnover of p62 protein.
When autophagy is suppressed, p62 protein clearance is prevented,
leading to its accumulation, which in turn activates NRF2 (nuclear factor
erythroid 2 related factor 2). NRF2 can then translocate to the nucleus,
where it activates an anti-oxidant and pro-survival response [117,
120–122].
Some of the Atg proteins act as tumor suppressor genes. Beclin 1
(Atg6) expression is suppressed in malignant breast epithelial cells,
and it is monoallelically deleted in 40–70% of prostate, ovarian, and
breast cancers. Overexpression of Beclin 1 in breast cancer cells promoted
autophagy and inhibited the malignant phenotype [123–125]. In vivo,
targeted deletion of Beclin 1 in mice led to early embryonic death.
Heterozygous disruption of Beclin 1 resulted in an increased risk of spon-
taneous tumor development, even though the other allele is intact. This
suggests that the pro-autophagic Beclin 1 is a haplo-insufﬁcient tumor
suppressor protein [126]. Further studies then highlighted that other
pro-autophagic proteins also act as tumor suppressors, such as Atg5 and
Bif1 [83,84,112]. Autophagy can also be suppressed due to its regulation
by signaling pathways that are up- or down-regulated in the cancer
cells [112]. For instance, cancer cells with upregulation of PI3K-AKT-
mTOR signaling cascade, or downregulation of PTEN activity, will
have suppressed autophagy, promoting tumor growth/proliferaiton
[83,127,128].
As cancer progresses to late stages, autophagy can act as amechanism
to help the cancer cells meet metabolic demands and repair intracellular
damages inﬂicted by the aggressive tumor environment [84,112,119].
Pancreatic cancer cell lines demonstrate a high basal rate of autophagy,
and upon pharmacological inhibition of autophagy by chloroquine,
pancreatic cancer cell growth was diminished mainly due to increased
DNA damage and oxidative stress [117,129]. Additionally, cancer cells
expressing the Ras oncogene have a higher basal rate of autophagy,
such that Ras expressing Atg5−/− and Atg7−/− cells, have sup-
pressed autophagy levels and showed reduced tumor growth in vivo
[130].
The implication of autophagy in cancer pathogenesis gives insight
into new pharmacological therapies for cancer. If autophagy is required
for the survival of cancer cells in the late stages, then pharmacological
inhibition of autophagy can enhance the anti-cancerous effect of
chemotherapeutic drugs [84,112,112,117,120]. For instance, combining
vinblastine with C6-ceramide attenuated autophagy and inhibited
cancer cell growth in a synergistic fashion [131]. In contrast, if autophagy
induction leads to cancer cell death via lethal autophagy, then drugs
that induce autophagy will lead to tumor suppression. For example,
pyridinium ceramide treatment leads to cancer cell death via in part
activating autophagy [11].
3.4. Role of ceramide in mediating general autophagy
Ceramide is known to induce both survival and lethal autophagy
via several mechanisms that are outlined in Fig. 2 [4,132,133]. One
mechanismbywhich ceramide can induce survival autophagy is by reg-
ulating cellular nutrient transporters [134–136]. Transporter proteins
Fig. 2. Ceramide's role in survival and lethal autophagy. Ceramide regulates several signaling pathways in autophagy, some of which lead to cytoprotective autophagy and survival while
some lead to cell death through lethal autophagy. In the context of survival autophagy, ceramide can induce ER stress that activates the pro-survival IRE1 (inositol-requiring element 1),
downregulate nutrient transporters and improves catabolicmetabolism, and can result in activation of Atg5 via CD95 and PERK. In the context of lethal autophagy, ceramide can induce ER
stress that inhibits mTOR through TRB3, activate ceramide associated phosphatases (CAPPs) that also inhibit mTOR by inactivating Akt, increase the expression of Beclin-1 by activating
JNK-c-Jun axis or by inactivating Bax, leading to loss of mitochondrial membrane potential and activation of BNIP3, and bind to LC3-II to recruit autophagosomes to engulf mitochondria.
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Since these transporters control the cellular fuel supply, alteration of
the expression of the nutrient transporters is one way to affect sur-
vival and cell growth. Ceramide was shown to down-regulate the ex-
pression of amino acid and nutrient transporters leading to
starvation, a state that induces survival autophagy by reducing
mTOR signaling or activating AMPK [135,137]. Survival autophagy
was also induced in the context of CerS2 downregulation that dys-
regulated the normal trafﬁcking of ceramide in the ER, leading to
long chain ceramide accumulation, and activation of pro-survival
IRE-1 (inositol requiring element 1) to prevent induction of cell death
[133].
Moreover, ceramide is shown to induce lethal autophagy by affecting
the expression of pro-autophagic protein Beclin 1 whereby exogenous
treatment of cells with C2-ceramide increased Beclin 1 expression and
induced lethal autophagy [138]. This is due to the conversion of
C2-ceramide to long chain ceramide as the effect was inhibited when
de novo ceramide synthesiswas blocked usingmyriocin, the pharmaco-
logical inhibitor of SPT [138]. Further evidence indicated that ceramide
increases Beclin 1 expression by activating JNK kinase, which in turn ac-
tivates c-Jun, a known transcription factor for Beclin 1 expression [139].
In addition, JNK activation by ceramide leads to Bcl2 phosphorylation
allowing it to dissociate from Beclin 1 [140]. In addition, chemothera-
peutic drugs and arsenic trioxide lead to ceramide production that in-
crease Beclin1 expression and promote lethal autophagy [141]. Other
drugs such as cannabinoids also lead to ceramide accumulation to in-
duce ER stress, mTOR inhibition via TRB3 (tribbles homologue 3), and
lethal autophagy [142].
Ceramide can be hydrolyzed for the generation of S1P, which plays
important roles in the regulation of autophagy [19,143]. When cells
were subjected to starvation, the activity of sphingosine kinase 1
(SphK1) increased, leading to increased accumulation of S1P [144].
SphK1 overexpression was able to induce autophagy by inhibiting the
mTOR pathway, but unlike the case of ceramide, this mechanism was
independent of AKT dephosphorylation [143–145]. In addition, SphK1downregulation enhanced ER stress and induced autophagy in an
mTOR independent fashion [146].4. Ceramide-mediated mitophagy
4.1. Mitophagy: selective autophagy of the mitochondria
Autophagy was considered to be a general process whereby the
autophagosomes engulf many cytoplasmic elements, including mito-
chondria, endoplasmic reticulum, and peroxisomes [147]. However,
recent ﬁndings suggest that autophagy can be selective to a speciﬁc or-
ganelle. The ﬁndings are based on the discovery of speciﬁc proteins of
the organelles that are required to instigate the autophagy process.
These include peroxin 14 of peroxisomes in yeast for pexophagy, the
autophagic degradation of peroxisomes; and Uth1p, an outer mitochon-
drial membrane protein required for selective mitochondrial autophagy,
also known as mitophagy [148–150].
Aged and dysfunctional mitochondria are removed from cells to
prevent the harm of unhealthy mitochondria, which generate reactive
oxygen species, and release pro-apoptotic proteins [151]. This turnover
process involves the action of autophagosomes and lysosomal hydrolytic
enzymes. The termmitophagyhas been suggested to refer to suchprocess
that selectively removes the mitochondria by autophagy [151–153].
It has been shown that mitochondria in hepatocytes that had un-
dergone a mitochondrial permeability transition or a depolarization
of themitochondrial membrane potential are selectively removed by
autophagosomes [153]. These studies showed that upon loss of mito-
chondrial membrane potential or duringmitochondrial permeability
transition, mitochondria are engulfed by GFP-LC3 positive auto-
phagosomes [9,154]. Photo-damaged mitochondria also recruited
GFP-LC3 positive structures to the damaged areas [155]. It is suggested
that reactive oxygen species (ROS) act as a signal in damagedmitochon-
dria to recruit the LC3 positive autophagosomes. ROS can activate Atg4B,
the protease that is required for LC3-I to be converted to LC3-II [156,157].
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It is proposed that there are at least three types of mitophagy de-
pending on the cellular mechanism of sequestration of mitochondria
into autophagosomes [152].
Type 1 mitophagy refers to the mitophagy process that occurs during
nutrient deprivation. The process occurs in coordination with mitochon-
drial ﬁssion, which starts with the formation of phagophores that enlarge
to surround mitochondria to form structures called mitophagosomes.
Mitophagosomes are then acidiﬁed to activate the hydrolytic enzymes
of lysosomes [152,155,158].
Type 2 mitophagy refers to the degradation of mitochondria during
photo damage. In this case, depolarizedmitochondria recruit LC3 positive
structures to aggregate onto their surface. These structures then fuse to-
gether to sequester the mitochondria into a mitophagosome [159–161].
This type ofmitophagy is not coordinatedwithmitochondrialﬁssion, un-
like Type 1. Another difference is that Beclin-1 protein is required for
Type 1 mitophagy but not for Type 2. This came from studies showing
that Type 1 mitophagy can be prevented by pharmacological inhibition
of PI3K using 3-methyladenine or wortmannin. On the other hand,
Type 2 mitophagy was shown to be independent of Beclin-1 and PI3K
[152].
Type 3 mitophagy, also known as micromitophagy, involves the
formation of mitochondria-derived vesicles, which translocate to the
lysosomes [152,162,163]. The release of mitochondrial derived vesicles
depends on oxidative stress in the mitochondria and involves pink 1
and parkin proteins. Micromitophagy does not involve LC3 or Atg5,
and it is independent of mitochondrial depolarization or mitochondrial
ﬁssion [164]. This process allows the cell to selectively remove damaged
or oxidized components of themitochondria without total degradation.
4.3. Progression of mitophagy and the involvement of mitochondrial
ﬁssion/fusion
The signaling pathways involved in the progression of mitophagy
share many similarities with general autophagy. At baseline, LC3 is dis-
persed throughout the cytosol, and some LC3 is found in pre-autophagic
structures close to the mitochondrial membrane [80]. During mitophagy,
LC3 is conjugated to phosphatidylethanolamine (PE), forming LC3-II.
During type 1 mitophagy, already existing preautophagic structures
enlarge in size to envelope and sequester the mitochondria. This event
forms themitophagosome,which then fuseswith a lysosome or a late en-
dosome to form a mitophagolysosome that digests the mitochondrial
content [152,155].
Themolecular events contributing tomitophagy initiationwere ﬁrst
identiﬁed in yeast. Studies showed that there are three yeast proteins
participating in mitophagy initiation: outer mitochondrial protein Uth1,
intermembrane space protein phosphatase Aup1, and inner membrane
protein required for K+/H+ exchange Mdm38p [9]. Atg32 was identiﬁed
as the main signal to direct autophagosomes to mitochondria after
interacting with Atg8 and Atg11 [165,166,202]. There are nomammalian
homologues for Atg32; however, studies showed that there are some
receptors on the mitochondrial outer membrane that signal for the
mitophagy process. For instance, optineurin acts as an autophagy recep-
tor in parkin-mediated mitophagy, and FUNDC1 mediates hypoxia
induced mitophagy [196,197]. Autophagy receptors can also be lipids
in the mitochondrial membrane such as cardiolipin and ceramide
[14,198,199].
Moreover, proteins involved in mitochondria ﬁssion/fusion are key
regulators for the selective elimination of mitochondria in mammalian
cells [167]. Mitochondria are dynamic mobile organelles continuously
dividing or fusing [147]. The processes of fusion and ﬁssion are intrinsic
for mitochondrial viability, and they are important in the regulation of
calcium homeostasis and the generation of ATP and ROS [168,169].
In addition, ﬁssion and fusion of the mitochondria are important
during mitophagy [9]. Fission, or mitochondrial division, involvesthe translocation of DRP-1 (dynamin related protein 1) to the mito-
chondria, where it oligomerizes to bind to Fission 1 (Fis1) in the
outer mitochondrial membrane [170]. Fusion, a process that fuses
two mitochondria together, involves mitofusin 1 and mitofusin 2, lo-
cated in the outer mitochondrial membrane, and OPA1 (optic atro-
phy protein 1) located in the inner mitochondrial membrane [171].
OPA1 is processed by mitochondrial peptidase OMA1 and i-AAA pro-
tease YME1L and is regulated bymitofusin 1 during innermitochondri-
al membrane fusion [200,201].
The role of ﬁssion and fusion during the mitophagy process is illus-
trated in several studies. Cells with a knockdown of DRP-1 had sup-
pressed rates of mitophagy, whereas cells with overexpression of DRP-1
had excessivemitochondrial disappearance [172–174]. In addition,mito-
chondria going through a round of fusion followed by ﬁssion generate
two populations of mitochondria: those that re-fuse and are healthy,
and those that never re-fuse, have a depolarized membrane potential,
and get degraded by mitophagy [173,175]. The loss of the pro-fusion
OPA-1 is a key process for mitophagy, such that OPA-1 overexpression
was able to decrease mitophagy [173,175].
The pro-ﬁssion function of DRP-1makes it an important player during
mitophagy. DRP-1 is a cytosolic GTPase with three domains: GTP binding
domain, bundle signaling element (BSE), and a stalk that allows for stable
dimerization and oligomerization [176]. Upon its activation, DRP-1 trans-
locates to themitochondria to form dimers and oligomers that are neces-
sary for ﬁssion. It is believed that DRP-1 translocation requires adapter
proteins, such as mitochondrial ﬁssion factor (MFF), mitochondrial
elongation factor 1/mitochondrial dynamics proteins of 49 and
51 kDa (MIEF1/MiD49/MiD51), and mitochondrial ﬁssion protein
Fis1 [177–181]. DRP-1 is regulated by several post-transcriptional modi-
ﬁcations such as phosphorylation. There are two sites of phosphorylation
for DRP-1: Ser637 and Ser616. DRP-1 is activated when it is phosphory-
lated by cyclin B1-CDK1 at Ser616 and dephosphorylated by calcineurin
at Ser637 [170,182]. DRP-1 is inactivated when it is phosphorylated
by protein kinase A at Ser637 [170,182]. Another form of regulation of
DRP-1 is nitrosylation by nitric oxide in the mitochondria, and
deSUMOylation by SENP5 protease, both of which promote DRP-1 acti-
vation and dimer formation [182].
Two other proteins, which are associated with Parkinson's disease,
are involved in DRP-1 mediated mitophagy: pink1 and parkin. Pink1 is
a serine/threonine protein kinase located inside the mitochondria,
while parkin is anE3ubiquitin protein ligase locatedmainly in the cytosol
[183–186]. It is believed that Parkin and Pink1 promote mitochondrial
ﬁssion such that silencing their expression leads tomitochondrial defects
due to lack of ﬁssion [184,187]. Pink 1 and Parkin also regulate other mi-
tochondrial functions, includingmitochondrial biogenesis, mitochondrial
transport, and calcium homeostasis [188–192]. In healthy mitochondria,
Pink1 is cleaved and exported to the cytosol where it is rapidly degraded
by proteasomes [200–202]. Upon uncoupling or depolarization of themi-
tochondria, Pink1 is stabilized, and Parkin is translocated from the cytosol
to themitochondria in a Pink 1-dependent fashion. This leads to ubiquitin
mediated proteasomal degradation of outer mitochondrial proteins such
as mitofusin 1 and mitofusin 2, leading to mitochondrial fragmentation
and initiation of mitophagy [177,184,193]. DRP-1 is recruited to mito-
chondrial sites in close proximity of Pink1 and Parkin highlighting their
importance in DRP-1-dependent mitophagy. In addition, Parkin can in-
duce mitochondrial ﬁssion independent of Pink1 by affecting DRP-1
phosphorylation [184].
Moreover, ROS serve as candidates to initiate mitophagy. Cells
supplied exogenously with hydrogen peroxide or superoxide showed
evidence of autophagosomal structure formation [166]. It has been
shown that upon ROS generation in themitochondria, the mitochondrial
membranewas depolarized, leading to Parkin translocation and initiation
of mitophagy [195]. Interestingly, overexpression of the anti-oxidant
enzyme superoxide dismutase 2 or pre-treatment with antioxidants
prevented ROS-induced mitophagy [194,195]. This suggests that oxida-
tive stress may be an important signal to initiate mitophagy.
Fig. 3. Regulation of mitophagy by ceramide. Endogenous generation of C18-ceramide via
CerS1 or exogenous treatment by C18-pyridinium-ceramide is followed by two processes:
A. conjugation of LC3-I to phosphatidylethanolamine on the carboxy terminal to form LC3-II
and B. accumulation of ceramide in themitochondrial outermembrane. Ceramide in themi-
tochondrialmembrane acts as a receptor to LC3-II by binding to its amino terminal, opposite
to where PE is conjugated. This results in C. recruiting the autophagosome to engulf the mi-
tochondria. Lysosomes then fusewith the autophagosomes (D) for hydrolytic degradation of
the contents.
2840 M. Dany, B. Ogretmen / Biochimica et Biophysica Acta 1853 (2015) 2834–28454.4. Ceramide mediated mitophagy as a tumor suppressor mechanism
There is evidence to support a role for mitophagy in cell survival or
death, which appears to be context dependent. Mitophagy promotes
cell survival under circumstances where it degrades the mitochondria
that are about to activate caspase dependent apoptosis. In this case,
disrupting the autophagic and lysosomal processeswill prevent survival
and lead to apoptosis [152,153]. On the other hand, when mitophagy
occurs excessively or for a sustained period of time, enzymes from the
lysosomalﬂux such as cathepsins can leak to the cytosol where they ini-
tiate caspase dependent cell death [79,83,152]. Therefore, the functional
outcome of mitophagy inducing cell death or survival depends on the
intensity and duration of the stress as well as cellular contact [152].
Moreover, mitophagy can serve as a programmed cell death mecha-
nism independent of apoptosis. This mechanism of cell death depends
on ceramide synthase 1 (CerS1) and its metabolic product C18-ceramide.
Sentelle et al. showed that CerS1 and C18-ceramide selectively induce
non-apoptotic lethal mitophagy independent of Bax, Bak, or caspase
activity, in head and neck squamous cell carcinoma cells and tumors.
Ectopic expression of CerS1 or treatment with C18-pyridinium-ceramide
resulted in LC3-II formation, and promoted its direct binding to ceramide
on the mitochondrial membranes. This lipid–protein binding then
allowed the mitochondria to be targeted by the LC3-II containing
autophagosomes. This reportwas theﬁrst to describe the role of ceramide
signaling inmediating lethalmitophagy through ceramide-LC3-II binding
(Fig. 3). Interestingly, endogenous C16-ceramide generated by CerS6 did
not show any mitophagy promoting function in these cells. However,
treatmentwithC16-pyridiniumceramide,which accumulates in themito-
chondria, inducedmitophagy. This suggested that the subcellular localiza-
tion of endogenous ceramides, and not their fatty acid chain length per se,
is of great importance to determine their distinct biological actions during
mitophagy [14].
The binding of ceramide to LC3-II indicates that ceramide acts as a
tumor suppressor lipid that can directly bind proteins. Ceramide is
shown to have a higher afﬁnity to the PE-conjugated LC3-II than LC3-I.
This interaction was proposed to involve the central hydrophobic
domain of LC3 that has structural similarities to the domain of CERT
(ceramide transporter protein) that binds C16- and C18-ceramides.
Within this hydrophobic domain, the Ile35 and Phe52 residues of LC3-II
were required for ceramide binding. Computational docking simulations
andmolecular modeling suggested that conjugation of LC3-I to phospha-
tidylethanolamine hides a low-afﬁnity ceramide-binding sites allowing
ceramide to bind selectively to the opposite end of the protein [14,49].
More importantly, although point mutations at the Ile35 and/or Phe52
for conversion to Ala did not prevent ceramide-mediated LC3 lipidation,
and inhibition of ceramide binding modulated mitophagy and resulted
in resistance to ceramide-mediated tumor suppression. Thus, these data
support that ceramide plays a novel receptor role at the mitochondrial
membranes to recruit LC3-II-containing autophagosomes to the mito-
chondria, which have been subjected to DRP-1-mediated ﬁssion. These
data also suggest that targeting LC3 containing autophagosomes to mito-
chondria by ceramide at the mitochondrial membranes results in cancer
cell death and tumor suppression, which seems to be regulated down-
stream of DRP1-mediated mitochondrial ﬁssion. Interestingly, in the
absence of CerS1 overexpression, tumor cells with knockdown of LC3
had a reduced growth in vivo suggesting that at baseline, LC3 mediated
autophagy is required for tumor growth in head and neck squamous
cell carcinoma tumors [14,49].
5. Conclusions and future perspectives
Ceramide, as a bioactive sphingolipid, plays key roles in the regula-
tion of general and selective autophagy and/or mitophagy. This role of
ceramide is of great importance in tumor biology as in most cases
ceramide mediated autophagy leads to cell death and is thus called
lethal autophagy or autosis [108,114]. One example by which ceramideregulates lethal autophagic signaling pathways is its activation of c-Jun
through JNK signaling, causing upregulated Beclin 1 expression and
autophagic cell death [138]. Exogenous supply of C18-pyridinium cer-
amide or overexpression of CerS1 resulted in caspase independent
mitophagy where ceramide acts as a mitochondrial receptor for LC3-
II-containing autophagosomes by interacting directly with LC3-II,
recruiting autophagolysosomes to damaged mitochondria [14]. Exoge-
nous ceramide mediated autophagic cell death is believed to involve
BNIP3 activation after a reduction in mitochondrial membrane potential
[140]. Chemotherapeutic drugs and arsenic trioxide lead to ceramide pro-
duction that increases Beclin1 expression and promotes lethal autophagy
[141]. Other drugs such as cannabinoids also lead to ceramide accumula-
tion to induce ER stress, mTOR inhibition via TRB3 (tribbles homologue
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duce lethal autophagy in a ceramide dependent manner by activating
CAPPs (ceramide activated protein phosphatases), which inhibits
Akt/mTOR pathway [8]. The knowledge of the role of ceramide in au-
tophagy/mitophagy sets an example to the importance of sphingolipid
metabolism and signaling in these cellular mechanisms. Thus, more
studies should be invested in this area of research to deﬁne the roles
and mechanisms of how ceramide and/or other bioactive sphingolipid
molecules mediate mitophagy and their relation to mitochondrial
dynamics. Ceramide's role in recruiting autophagosomes speciﬁcally to
mitochondria gave support to the ﬁndings that removal of mitochondria
by autophagy can be selective rather than inadvertent. Ceramide acts as a
receptor in the mitochondria binding the LC3-II in the autophagosomes
to direct themspeciﬁcally tomitochondria. However, the relationship be-
tween ceramide and the ﬁssion/fusion machinery is still not clear. DRP-1
is required for ceramide-mediated mitophagy, however the mechanism
underlying DRP-1 activation remains unknown. Other studies looking
at the interplay of ceramide and Pink1 or Parkin are also important for
the ﬁeld. Importantly, studies should consider the compartmentalized
roles of ceramides with different fatty acyl chain lengths, involved in
the regulation of the mitophagy process. We expect that there will be
key discoveries to dissect the mechanisms of how ceramide regulates
lethal mitophagy and tumor suppression during the next few years, as
analytical, molecular, pharmacologic and/or genetic tools are now avail-
able to deﬁne these roles of ceramides/sphingoilipids in various disease
models.
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